Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 9, 2004, Pages 1735-1751

  Domaoal, Robert A ^a   Demeter, Lisa M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Drug resistance; Human immunodeficiency virus type 1; K103N; Non nucleoside reverse transcriptase inhibitors; Reverse transcriptase

Indexed keywords

ANTIVIRUS AGENT; DELAVIRDINE; DIDANOSINE; DNA; EFAVIRENZ; LOVIRIDE; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; QUINOXALINE DERIVATIVE; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; S 2720; STAVUDINE; TALVIRALINE; TETRAHYDROBENZODIAZEPINE DERIVATIVE; THYMIDINE TRIPHOSPHATE; UNCLASSIFIED DRUG; ZIDOVUDINE;

CATALYSIS; DRUG BINDING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; POLYMERIZATION; REVIEW; RNA CLEAVAGE; VIRUS MORPHOLOGY; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION;

CODON; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 2942565660     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.02.026     Document Type: Review

References (95)

1. Archer R.H., Dykes C., Gerondelis P., Lloyd A., Fay P., Reichman R.C., et al. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. Journal of Virology. 74:2000;8390-8401
2. Archer R.H., Wisniewski M., Bambara R.A., Demeter L.M. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry. 40:2001;4087-4095
3. Arnold E., Jacobo-Molina A., Nanni R.G., Williams R.L., Lu X., Ding J., et al. Structure of HIV-1 reverse transcriptase/DNA complex at 7 Å resolution showing active site locations. Nature. 357:1992;85-89
4. Baba M., Tanaka H., De Clercq E., Pauwels R., Balzarini J., Schols D., et al. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochemical and Biophysical Research Communications. 165:1989;1375-1381
5. Bacheler L.T., Anton E.D., Kudish P., Baker D., Bunville J., Krakowski K., et al. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents and Chemotherapy. 44:2000;2475-2484
6. Bacheler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of Virology. 75:2001;4999-5008
7. Bacolla A., Shih C.K., Rose J.M., Piras G., Warren T.C., Grygon C.A., et al. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs. Journal of Biological Chemistry. 268:1993;16571-16577
8. Balzarini J., De Clercq E., Carbonez A., Burt V., Kleim J.P. Long-term exposure of HIV type 1-infected cell cultures to combinations of the novel quinoxaline GW420867X with lamivudine, abacavir, and a variety of nonnucleoside reverse transcriptase inhibitors. AIDS Research and Human Retroviruses. 16:2000;517-528
9. Boyer P.L., Currens M.J., McMahon J.B., Boyd M.R., Hughes S.H. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase. Journal of Virology. 67:1993;2412-2420
10. Boyer P.L., Ferris A.L., Clark P., Whitmer J., Frank P., Tantillo C., et al. Mutational analysis of the fingers and palm subdomains of human immunodeficiency virus type-1 (HIV-1) reverse transcriptase. Journal of Molecular Biology. 243:1994;472-483
11. Boyer P.L., Gao H.Q., Hughes S.H. A mutation at position 190 of human immunodeficiency virus type 1 reverse transcriptase interacts with mutations at positions 74 and 75 via the template primer. Antimicrobial Agents and Chemotherapy. 42:1998;447-452
12. Byrnes V.W., Emini E.A., Schleif W.A., Condra J.H., Schneider C.L., Long W.J., et al. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 38:1994;1404-1407
13. Byrnes V.W., Sardana V.V., Schleif W.A., Condra J.H., Waterbury J.A., Wolfgang J.A., et al. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors. Antimicrobial Agents and Chemotherapy. 37:1993;1576-1579
14. Carroll S.S., Geib J., Olsen D.B., Stahlhut M., Shafer J.A., Kuo L.C. Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry. 33:1994;2113-2120
15. Coffin J.M. HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science. 267:1995;483-489
16. Das K., Ding J., Hsiou Y., Clark A.D. Jr., Moereels H., Koymans L., et al. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant. Journal of Molecular Biology. 264:1996;1085-1100
17. Debyser Z., De Vreese K., Knops-Gerrits P.P., Baekelandt V., Bhikhabhai R., Strandberg B., et al. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors. Molecular Pharmacology. 43:1993;521-526
18. Demeter L.M., Shafer R.W., Meehan P.M., Holden-Wiltse J., Fischl M.A., Freimuth W.W., et al. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial Agents and Chemotherapy. 44:2000;794-797
19. Descamps D., Collin G., Letourneur F., Apetrei C., Damond F., Loussert-Ajaka I., et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: In vitro phenotypic and genotypic analyses. Journal of Virology. 71:1997;8893-8898
20. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A., et al. Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Structural Biology. 2:1995a;407-415
21. Ding J., Das K., Tantillo C., Zhang W., Clark A.D. Jr., Jessen S., et al. Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution. Structure. 3:1995b;365-379
22. Domaoal, R. A., Bambara, R. A., & Demeter, L. M. (2003). HIV-1 reverse transcriptases resistant to non-nucleoside reverse transcriptase inhibitors have different effects on the kinetics of single nucleotide incorporation. In Proceedings of the 10th conference on retroviruses and opportunistic infections (Abstract no. 612).
23. Dueweke T.J., Kezdy F.J., Waszak G.A., Deibel M.R. Jr., Tarpley W.G. The binding of a novel bisheteroarylpiperazine mediates inhibition of human immunodeficiency virus type 1 reverse transcriptase. Journal of Biological Chemistry. 267:1992;27-30
24. Dueweke T.J., Poppe S.M., Romero D.L., Swaney S.M., So A.G., Downey K.M., et al. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy. 37:1993a;1127-1131
25. Dueweke T.J., Pushkarskaya T., Poppe S.M., Swaney S.M., Zhao J.Q., Chen I.S., et al. A mutation in reverse transcriptase of bis(heteroaryl)piperazine- resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 90:1993b;4713-4717
26. Dykes C., Fox K., Lloyd A., Chiulli M., Morse E., Demeter L.M. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology. 285:2001;193-203
27. Esnouf R.M., Ren J., Hopkins A.L., Ross C.K., Jones E.Y., Stammers D.K., et al. Unique features in the structure of the complex between HIV-1 reverse transcriptase and the bis(heteroaryl)piperazine (BHAP) U-90152 explain resistance mutations for this nonnucleoside inhibitor. Proceedings of the National Academy of Sciences of the United States of America. 94:1997;3984-3989
28. Esnouf R., Ren J., Ross C., Jones Y., Stammers D., Stuart D. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nature Structural Biology. 2:1995;303-308
29. Fan N., Evans D.B., Rank K.B., Thomas R.C., Tarpley W.G., Sharma S.K. Mechanism of resistance to U-90152S and sensitization to L-697, 661 by a proline to leucine change at residue 236 of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. FEBS Letters. 359:1995;233-238
30. Fan N., Rank K.B., Slade D.E., Poppe S.M., Evans D.B., Kopta L.A., et al. A drug resistance mutation in the inhibitor binding pocket of human immunodeficiency virus type 1 reverse transcriptase impairs DNA synthesis and RNA degradation. Biochemistry. 35:1996;9737-9745
31. Frank K.B., Noll G.J., Connell E.V., Sim I.S. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4, 5, 1-jk]-[1, 4]-benzodiazepine-2-(1H)-thione compound, R82150. Journal of Biological Chemistry. 266:1991;14232-14236
32. Gerondelis P., Archer R.H., Palaniappan C., Reichman R.C., Fay P.J., Bambara R.A., et al. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5′-end- and DNA 3′-end-directed RNase H activities. Journal of Virology. 73:1999;5803-5813
33. Goff S.P. Retroviral reverse transcriptase: Synthesis, structure, and function. Journal of Acquired Immune Deficiency Syndromes. 3:1990;817-831
34. Goldman M.E., Nunberg J.H., O'Brien J.A., Quintero J.C., Schleif W.A., Freund K.F., et al. Pyridinone derivatives: Specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proceedings of the National Academy of Sciences of the United States of America. 88:1991;6863-6867
35. Havlir D.V., Eastman S., Gamst A., Richman D.D. Nevirapine-resistant human immunodeficiency virus: Kinetics of replication and estimated prevalence in untreated patients. Journal of Virology. 70:1996;7894-7899
36. Hopkins A.L., Ren J., Esnouf R.M., Willcox B.E., Jones E.Y., Ross C., et al. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. Journal of Medical Chemistry. 39:1996;1589-1600
37. Hsiou Y., Das K., Ding J., Clark A.D. Jr., Kleim J.P., M R.S., et al. Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: Inhibitor flexibility is a useful design feature for reducing drug resistance. Journal of Molecular Biology. 284:1998;313-323
38. Hsiou Y., Ding J., Das K., Clark A.D. Jr., Hughes S.H., Arnold E. Structure of unliganded HIV-1 reverse transcriptase at 2.7 Å resolution: Implications of conformational changes for polymerization and inhibition mechanisms. Structure. 4:1996;853-860
39. Hsiou Y., Ding J., Das K., Clark A.D. Jr., Boyer P.L., Lewi P., et al. The Lys103Asn mutation of HIV-1 RT: A novel mechanism of drug resistance. Journal of Molecular Biology. 309:2001;437-445
40. Huang W., Gamarnik A., Limoli K., Petropoulos C.J., Whitcomb J.M. Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. Journal of Virology. 77:2003;1512-1523
41. Iglesias-Ussel M.D., Casado C., Yuste E., Olivares I., Lopez-Galindez C. In vitro analysis of human immunodeficiency virus type 1 resistance to nevirapine and fitness determination of resistant variants. Journal of General Virology. 83:2002;93-101
42. Jacobo-Molina A., Ding J., Nanni R.G., Clark A.D. Jr., Lu X., Tantillo C., et al. Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proceedings of the National Academy of Sciences of the United States of America. 90:1993;6320-6324
43. Jeffrey J.L., Feng J.Y., Qi C.C., Anderson K.S., Furman P.A. Dioxolane guanosine 5′-triphosphate, an alternative substrate inhibitor of wild-type and mutant HIV-1 reverse transcriptase. Steady state and pre-steady state kinetic analyses. Journal of Biological Chemistry. 278:2003;18971-18979
44. Johnson K.A. Rapid kinetic analysis of mechanochemical adenosinetriphosphatases. Methods in Enzymology. 134:1986;677-705
45. Klaver B., Berkhout B. Premature strand transfer by the HIV-1 reverse transcriptase during strong-stop DNA synthesis. Nucleic Acids Research. 22:1994;137-144
46. Kleim J.P., Bender R., Billhardt U.M., Meichsner C., Riess G., Rosner M., et al. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrobial Agents and Chemotherapy. 37:1993;1659-1664
47. Kleim J.P., Bender R., Kirsch R., Meichsner C., Paessens A., Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 200:1994;696-701
48. Kleim J.P., Bender R., Kirsch R., Meichsner C., Paessens A., Rosner M., et al. Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication. Antimicrobial Agents and Chemotherapy. 39:1995;2253-2257
49. Kleim J.P., Rosner M., Winkler I., Paessens A., Kirsch R., Hsiou Y., et al. Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants. Proceedings of the National Academy of Sciences of the United States of America. 93:1996;34-38
50. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 256:1992;1783-1790
51. Kroeger Smith M.B., Michejda C.J., Hughes S.H., Boyer P.L., Janssen P.A., Andries K., et al. Molecular modeling of HIV-1 reverse transcriptase drug-resistant mutant strains: Implications for the mechanism of polymerase action. Protein Engineering. 10:1997;1379-1383
52. Lacey S.F., Larder B.A. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′, 3′-didehydro-2′, 3′-dideoxythymidine in cell culture. Antimicrobial Agents and Chemotherapy. 38:1994;1428-1432
53. Larder B.A. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrobial Agents and Chemotherapy. 36:1992;2664-2669
54. Larder B.A., Stammers D.K. Closing in on drug resistance. Nature Structural Biology. 6:1999;103-106
55. Lindberg J., Sigurdsson S., Lowgren S., Andersson H.O., Sahlberg C., Noreen R., et al. Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. European Journal of Biochemistry. 269:2002;1670-1677
56. Maga G., Amacker M., Ruel N., Hubscher U., Spadari S. Resistance to nevirapine of HIV-1 reverse transcriptase mutants: Loss of stabilizing interactions and thermodynamic or steric barriers are induced by different single amino acid substitutions. Journal of Molecular Biology. 274:1997;738-747
57. Mellors J.W., Im G.J., Tramontano E., Winkler S.R., Medina D.J., Dutschman G.E., et al. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4, 5, 6, 7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4, 5, 1-jk][1, 4]benzodiazepin-2(1H)-thione (TIBO R82150). Molecular Pharmacology. 43:1993;11-16
58. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., et al. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science. 250:1990;1411-1413
59. Nanni R.G., Ding J., Jacobo-Molina A., Hughes S.H., Arnold E. Perspectives in Drug Discovery and Design. 1:1993;129-150
60. Nicastri E., Sarmati L., d'Ettorre G., Palmisano L., Parisi S.G., Uccella I., et al. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. Journal of Medical Virology. 69:2003;1-6
61. Nijhuis M., Deeks S., Boucher C. Implications of antiretroviral resistance on viral fitness. Current Opinion in Infectious Diseases. 14:2001;23-28
62. Olmsted R.A., Slade D.E., Kopta L.A., Poppe S.M., Poel T.J., Newport S.W., et al. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes. Journal of Virology. 70:1996;3698-3705
63. Palaniappan C., Wisniewski M., Jacques P.S., Le Grice S.F., Fay P.J., Bambara R.A. Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. Journal of Biological Chemistry. 272:1997;11157-11164
64. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Stoffels P., et al. Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proceedings of the National Academy of Sciences of the United States of America. 90:1993;1711-1715
65. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., et al. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature. 343:1990;470-474
66. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents and Chemotherapy. 44:2000;920-928
67. Quinones-Mateu M.E., Arts E.J. Fitness of drug-resistant HIV-1: Methodology and clinical implications. Drug Resistance Updates. 5:2002;224-233
68. Rayner M.M., Cordova B., Jackson D.A. Population dynamics studies of wild-type and drug-resistant mutant HIV in mixed infections. Virology. 236:1997;85-94
69. Ren J., Esnouf R., Garman E., Somers D., Ross C., Kirby I., et al. High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nature Structural Biology. 2:1995a;293-302
70. Ren J., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., et al. The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: Lessons for inhibitor design. Structure. 3:1995b;915-926
71. Ren J., Esnouf R.M., Hopkins A.L., Jones E.Y., Kirby I., Keeling J., et al. 3′-Azido-3′-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes. Proceedings of the National Academy of Sciences of the United States of America. 95:1998;9518-9523
72. Ren J., Milton J., Weaver K.L., Short S.A., Stuart D.I., Stammers D.K. Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Design. 8:2000;1089-1094
73. Repaske R., Hartley J.W., Kavlick M.F., O'Neill R.R., Austin J.B. Inhibition of RNase H activity and viral replication by single mutations in the 3′ region of Moloney murine leukemia virus reverse transcriptase. Journal of Virology. 63:1989;1460-1464
74. Richman D.D. The clinical significance of drug-resistance mutants of human immunodeficiency virus. Research in Virology. 143:1992;130-131
75. Richman D.D., Havlir D., Corbeil J., Looney D., Ignacio C., Spector S.A., et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology. 68:1994;1660-1666
76. Richman D., Rosenthal A.S., Skoog M., Eckner R.J., Chou T.C., Sabo J.P., et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrobial Agents and Chemotherapy. 35:1991;305-308
77. Rittinger K., Divita G., Goody R.S. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 92:1995;8046-8049
78. Rodgers D.W., Gamblin S.J., Harris B.A., Ray S., Culp J.S., Hellmig B., et al. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 92:1995;1222-1226
79. Romero D.L., Busso M., Tan C.K., Reusser F., Palmer J.R., Poppe S.M., et al. Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proceedings of the National Academy of Sciences of the United States of America. 88:1991;8806-8810
80. Sardana V.V., Emini E.A., Gotlib L., Graham D.J., Lineberger D.W., Long W.J., et al. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple nonnucleoside inhibitors. Journal of Biological Chemistry. 267:1992;17526-17530
81. Schinazi R.F., Larder B.A., Mellors J.W. Mutations in retroviral genes associated with drug resistance. International Antiviral News. 5:1997;129-142
82. Selmi B., Deval J., Alvarez K., Boretto J., Sarfati S., Guerreiro C., et al. The Y181C substitution in 3′-Azido-3′-deoxythymidine-resistant human immunodeficiency virus type 1 reverse transcriptase suppresses the ATP-mediated repair of the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated primer. Journal of Biological Chemistry. 278:1993;40464-40472
83. Shulman N., Zolopa A.R., Passaro D., Shafer R.W., Huang W., Katzenstein D., et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: Impact on virological response to efavirenz-based therapy. AIDS. 15:2001;1125-1132
84. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., et al. Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proceedings of the National Academy of Sciences of the United States of America. 91:1994;3911-3915
85. Spence R.A., Anderson K.S., Johnson K.A. HIV-1 reverse transcriptase resistance to nonnucleoside inhibitors. Biochemistry. 35:1996;1054-1063
86. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science. 267:1995;988-993
87. St. Clair M.H., Martin J.L., Tudor-Williams G., Bach M.C., Vavro C.L., King D.M., et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science. 253:1991;1557-1559
88. Tanese N., Goff S.P. Domain structure of the Moloney murine leukemia virus reverse transcriptase: Mutational analysis and separate expression of the DNA polymerase and RNase H activities. Proceedings of the National Academy of Sciences of the United States of America. 85:1988;1777-1781
89. Udier-Blagovic M., Tirado-Rives J., Jorgensen W.L. Validation of a model for the complex of HIV-1 reverse transcriptase with nonnucleoside inhibitor TMC125. Journal of American Chemical Society. 125:2003;6016-6017
90. Van Laethem K., Witvrouw M., Pannecouque C., Van Remoortel B., Schmit J.C., Esnouf R., et al. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS. 15:2001;553-561
91. Wang D.P., Rizzo R.C., Tirado-Rives J., Jorgensen W.L. Antiviral drug design: Computational analyses of the effects of the L100I mutation for HIV-RT on the binding of NNRTIs. Bioorganic and Medicinal Chemistry Letters. 11:2001;2799-2802
92. Whitcomb J.M., Huang W., Limoli K., Paxinos E., Wrin T., Skowron G., et al. Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates. AIDS. 16:2002;F41-F47
93. White E.L., Buckheit R.W. Jr., Ross L.J., Germany J.M., Andries K., et al. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer templates. Antiviral Research. 16:1991;257-266
94. Wu J.C., Warren T.C., Adams J., Proudfoot J., Skiles J., Raghavan P., et al. A novel dipyridodiazepinone inhibitor of HIV-1 reverse transcriptase acts through a nonsubstrate binding site. Biochemistry. 30:1991;2022-2026
95. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., et al. L-743, 726 (DMP-266): A novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrobial Agents and Chemotherapy. 39:1995;2602-2605